Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1
Article full text
The above video abstract and key points represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2023